Jul 29, 2025
Kedrion Biopharma Receives Orphan Drug Designation for COAGADEX® for Acquired Factor X Deficiency (aFXD) and Starts Clinical Trial to Evaluate Efficacy and Safety
Mar 21, 2025
Kedrion Expands Ryplazim Distribution Network for PLGD-1 Patients
Nov 21, 2024
FDA Approves Kedrion's Bolognana Facility for Production of First and Only Treatment for PLGD-1, Ryplazim®
Oct 02, 2024
Kedrion and Biotest complete long-term Exclusive Distribution Agreement for Yimmugo® in the US
Jul 01, 2024
Kedrion Selected by Biotest to Distribute its Immunoglobulin Yimmugo® in the U.S. Following Recent FDA Approval
Apr 29, 2024
Kedrion Announces Rare Disease Medicine RYPLAZIM® Now Available in US
Oct 22, 2020
Kedrion's Partner, Kamada Ltd, Signs a Supply Agreement with the Israeli Health Authorities for the Investigational Anti-COVID-19 Plasma-Derived Therapy
Oct 06, 2020
Kedrion Names Val Romberg As CEO
Aug 25, 2020
Leading Biotech Companies Kedrion Biopharma of Italy and Kamada Ltd. of Israel Continue Their Collaboration to Develop a New Anti-COVID Plasma-Based Treatment
Aug 19, 2020
Kamada and Kedrion Biopharma Announce Results of First and Only U.S. Post-Marketing Pediatric Trial of a Human Rabies Immune Globulin (HRIG); The Study Met Its Primary Objective
Apr 29, 2020
Leading Biotech Companies Kedrion Biopharma of Italy and Kamada Ltd. of Israel Announce Global Collaboration to Speed New Anti-COVID Plasma-Based Treatment
Apr 07, 2020
Italian Biotech Leader Hopes to Be Ready With Plasma-based Treatment for COVID-19 by Late Summer of 2020